Department of Precision Medicine, "Luigi Vanvitelli" University of Campania, Naples, Italy.
Sbarro Institute for Cancer Research and Molecular Medicine, Department of Biology, College of Science and Technology, Temple University, Philadelphia, Pennsylvania.
J Cell Physiol. 2019 Jun;234(6):9378-9386. doi: 10.1002/jcp.27622. Epub 2018 Dec 5.
Lung cancer (LC) is the most common type of cancer and the second cause of death worldwide in men and women after cardiovascular diseases. Non-small-cell lung cancer (NSCLC) is the most frequent type of LC occurring in 85% of cases. Developing new methods for early detection of NSCLC could substantially increase the chances of survival and, therefore, is an urgent task for current research. Nowadays, explosion in nanotechnology offers unprecedented opportunities for therapeutics and diagnosis applications. In this context, exploiting the bio-nano-interactions between nanoparticles (NPs) and biological fluids is an emerging field of research. Upon contact with biofluids, NPs are covered by a biomolecular coating referred to as "biomolecular corona" (BC). In this study, we exploited BC for discriminating between NSCLC patients and healthy volunteers. Blood samples from 10 NSCLC patients and 5 subjects without malignancy were allowed to interact with negatively charged lipid NPs, leading to the formation of a BC at the NP surface. After isolation, BCs were characterized by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). We found that the BCs of NSCLC patients was significantly different from that of healthy individuals. Statistical analysis of SDS-PAGE results allowed discriminating between NSCLC cancer patients and healthy subjects with 80% specificity, 80% sensitivity and a total discriminate correctness rate of 80%. While the results of the present investigation cannot be conclusive due to the small size of the data set, we have shown that exploitation of the BC is a promising approach for the early diagnosis of NSCLC.
肺癌(LC)是最常见的癌症类型,也是男性和女性全球范围内仅次于心血管疾病的第二大死亡原因。非小细胞肺癌(NSCLC)是最常见的 LC 类型,占 85%的病例。开发 NSCLC 的早期检测新方法可以大大提高生存机会,因此是当前研究的紧迫任务。如今,纳米技术的爆炸式发展为治疗和诊断应用提供了前所未有的机会。在这种情况下,利用纳米颗粒(NPs)与生物流体之间的生物-纳米相互作用是一个新兴的研究领域。与生物流体接触后, NPs 被一层生物分子覆盖,称为“生物分子冠”(BC)。在这项研究中,我们利用 BC 来区分 NSCLC 患者和健康志愿者。10 名 NSCLC 患者和 5 名无恶性肿瘤的受试者的血液样本被允许与带负电荷的脂质 NPs 相互作用,导致 NP 表面形成 BC。分离后,通过十二烷基硫酸钠聚丙烯酰胺凝胶电泳(SDS-PAGE)对 BC 进行了表征。我们发现,NSCLC 患者的 BC 与健康个体明显不同。对 SDS-PAGE 结果的统计分析允许以 80%的特异性、80%的敏感性和 80%的总判别正确率区分 NSCLC 癌症患者和健康受试者。虽然由于数据集较小,本研究的结果不能得出结论性的结论,但我们已经表明,利用 BC 是 NSCLC 早期诊断的一种很有前途的方法。